NMN Regulatory Status: What the FDA Reversal Did and Did Not Change

Quick answer: The FDA reversed its earlier position in letters dated 29 September 2025, concluding that NMN had been marketed as a supplement before it was authorised for drug investigation. That removes the categorical exclusion — but it does not remove the New Dietary Ingredient notification requirement, which is the part most buyers and most sellers have not caught up with.

What actually happened, in order

The confusion around NMN is not really about the ingredient. It is about a single clause in the Federal Food, Drug, and Cosmetic Act, and a three-year argument over how to read it.

2022. The FDA notified several companies that nicotinamide mononucleotide could not be marketed as a dietary supplement. The reasoning rested on the drug preclusion provision: a substance that has been authorised for investigation as a new drug, and for which substantial clinical investigations have been instituted and made public, is excluded from the definition of a dietary supplement. NMN had been taken into a drug investigation programme. On the FDA’s reading, that closed the door.

The practical effect was immediate and messy. Amazon delisted NMN products. Some manufacturers pulled inventory; others carried on selling, on the view that the agency’s position was an interpretation stated in letters rather than a rule with the force of law behind it. Consumers had no way to tell which sellers were which.

2023–2024. Citizen petitions were filed asking the FDA to reconsider. The central argument was that the preclusion clause contains an exception, and the exception applied here: the clause does not exclude a substance that was marketed as a dietary supplement or as a food before the drug authorisation. Industry groups argued NMN met that test. The Natural Products Association eventually took the dispute to court.

29 September 2025. The FDA responded to the petitions with letters amending its position. The agency applied what is usually called the race-to-market analysis and concluded that NMN was in fact marketed as a dietary supplement in the United States before it was authorised for drug investigation. The exception applied. The categorical exclusion was withdrawn.

What the reversal does not do

This is where most of the coverage stopped, and where the useful part begins.

NMN being eligible to be a dietary ingredient is not the same as NMN being cleared for sale by anyone who wants to sell it. NMN is a New Dietary Ingredient — an ingredient not present in the food supply in the United States before October 1994. Under DSHEA, a New Dietary Ingredient requires a premarket New Dietary Ingredient Notification (an NDIN) submitted to the FDA at least 75 days before marketing, containing the evidence on which the manufacturer bases its conclusion that the ingredient is reasonably expected to be safe.

That obligation survived the reversal completely intact. A product containing NMN from a source that has not gone through an accepted NDIN — either its own, or its supplier’s — is still subject to being treated as adulterated. The FDA said so explicitly in the same correspondence that lifted the exclusion.

So the honest summary of NMN‘s regulatory status is narrower than the headlines: NMN can lawfully be a dietary ingredient; a specific NMN product is lawful only if its ingredient source is covered by an accepted notification.

Why this is worth caring about as a buyer

Most supplement categories do not have this problem. Magnesium and vitamin D were in the food supply long before 1994 and carry no notification requirement at all. NMN is in the small group of ingredients where the paperwork behind the powder is a real variable between one seller and another.

The three-year period of ambiguity made that worse. During the years when the category was formally excluded, the sellers who continued anyway were, by definition, the ones least interested in the FDA’s view of the matter — and a good deal of that inventory is still moving. Independent testing over that period repeatedly turned up NMN products whose measured content did not match the label, including some with essentially none of the labelled ingredient.

The reversal did not retroactively improve any of that supply. It changed the legal question, not the contents of anyone’s capsules.

What to ask a seller

Four questions separate a documented product from an undocumented one. Any seller who cannot answer them has told you something.

Who manufactures the NMN, and is that source covered by an accepted NDIN? This is the specific question the current regulatory position turns on. “NMN is legal now” is not an answer to it.

Is there a batch-specific certificate of analysis? Not a certificate for some batch, at some point — one that matches the lot number on the bottle you are being sold.

Does the COA come from a third-party laboratory? A manufacturer’s in-house assay is better than nothing and worse than an independent one.

Does it test for identity and purity, or only content? A purity figure tells you what fraction is NMN. It does not tell you what the remainder is. Heavy metals and residual solvents belong on the same document.

Where things stand outside the US

The American reversal is not global, and this trips people up when they compare prices across borders. The European Union treats NMN under the Novel Food regulation, which requires authorisation before an ingredient may be sold — a separate process with a separate outcome. Other jurisdictions, including Australia and Canada, apply their own classification rules. A product legally sold in one market is not automatically legal in another, and cross-border ordering does not inherit the seller’s local status.

Common questions

Is NMN banned in the United States?
No. It was treated as excluded from the dietary supplement category between 2022 and September 2025. That position was withdrawn.

Does the reversal mean the FDA has approved NMN?
No, and this distinction matters. The FDA does not approve dietary supplements at all — not NMN, not vitamin C. What happened is that the agency withdrew a specific legal objection to NMN’s eligibility as a dietary ingredient. Approval is not a thing that exists in this category, and any seller describing their product as FDA-approved is telling you they do not understand the framework they operate in.

What about NR (nicotinamide riboside)?
NR sits in a different position. It went through the NDIN process and has accepted notifications behind it, which is why it stayed on shelves throughout the period when NMN was contested. The two are related compounds with different regulatory histories, and that history is not evidence about which one is better.

Has anything changed since the reversal?
The reversal is recent and the practical consequences — how aggressively notification requirements get enforced, whether more suppliers file — are still developing. If you are reading this some time after publication, the underlying letters are dated 29 September 2025, and that is the fixed point to check any newer claim against.

This article describes the regulatory status of an ingredient and is not medical advice, nor is it legal advice. Regulatory positions change; verify current status before making decisions that depend on it.